Savant Capital’s Atara Biotherapeutics ATRA Stock Holding History

Savant Capital’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5,272	Closed	-$91.5K	–	1270
2024 Q1	$91.5K	Buy	+5,272	New	+$93.6K	﹤0.01%	1075

Other funds holding ATRA

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Savant Capital's ATRA Position: Q2 2024 in Review

Savant Capital sold out of Atara Biotherapeutics (ATRA) in Q2 2024, closing a stake of 5,272 shares — an estimated $91.5K sold.

Savant Capital first reported a position in ATRA in Q1 2024 and held it in 1 quarter. The position peaked at $91.5K in Q1 2024. 48 funds tracked by Wall St. Rank hold ATRA as of Q2 2024.

Savant Capital reported no remaining Atara Biotherapeutics position as of Q2 2024 after selling out during the quarter.
Savant Capital sold 5,272 Atara Biotherapeutics shares in Q2 2024, an estimated $91.5K.
Savant Capital first reported a position in Atara Biotherapeutics in Q1 2024 and held it in 1 quarter.
Savant Capital's Atara Biotherapeutics position peaked at $91.5K in Q1 2024.
48 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2024.

Based on Savant Capital's 13F filing for Q2 2024, filed 5 Aug 2024.